Eupraxia Pharmaceuticals (EPRX)
NASDAQ:EPRX
EPRX Stock Chart & Stats
$7.10
-$0.02(-0.66%)
At close: 4:00 PM EST
$7.10
-$0.02(-0.66%)
Day’s Range― - ―
52-Week Range$4.19 - $9.32
Previous CloseN/A
Volume2.60K
Average Volume (3M)148.90K
Market Cap
$421.31M
Enterprise Value$168.31M
Total Cash (Recent Filing)$138.98M
Total Debt (Recent Filing)$2.01M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 07, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding65,326,950
10 Day Avg. Volume43,828
30 Day Avg. Volume148,898
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)5.04
Price to Sales (P/S)0.00
P/FCF Ratio-13.91
Enterprise Value/Market Cap0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-768.89
Enterprise Value/Ebitda-3.77
Forecast
1Y Price Target
$16.50Price Target Upside132.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.84
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery PlatformA proprietary DiffuSphere local delivery platform is a durable competitive asset: targeted, controlled‑release therapy can reduce systemic side effects, create clinical differentiation across urology and osteoarthritis, and enable multiple pipeline programs from one core technology.
Strengthened, Low-leverage Balance SheetVery low leverage and sizable equity provide resilience against near-term spending needs. This stronger capital structure reduces immediate refinancing pressure, allowing management to fund clinical programs longer and negotiate better financing terms when needed.
Cash Losses Reflect Operating ActivityFree cash flow tracking net loss closely indicates R&D spending is cash-based and transparent. That alignment improves forecastability of financing needs and reduces risk of hidden non-cash charges that could suddenly worsen reported liquidity or profitability.
Bears Say
Pre-revenue OperationsBeing pre-revenue is a persistent structural constraint: the company must fund development until commercialization, has no product cash flows to offset R&D, and remains dependent on external capital, lengthening the path to positive earnings and returns.
Accelerating Cash BurnMaterial and accelerating operating cash burn increases the probability of near‑term financing. Even with low leverage today, sustained negative FCF depletes buffers, risks dilution or costly debt, and constrains long‑term program funding and strategic flexibility.
Negative Returns And Widening LossesDeeply negative returns reflect that invested capital is not yet generating value. Widening net losses reduce capital efficiency and prolong the time before shareholders see returns, raising structural reliance on external capital and heightening execution risk.
Eupraxia Pharmaceuticals News
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was $4.19 and its highest was $9.32 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is $421.31M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Aug 07, 2026 which is in 46 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on May 12, 2026. The company reported -$0.223 earnings per share for the quarter, missing the consensus estimate of -$0.189 by -$0.034.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.22.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 65,326,950 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -$0.223 in its last earnings report, missing expectations of -$0.189. Following the earnings report the stock price went down -0.788%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in EPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eupraxia Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.50 (132.39% Upside)
$16.50 (132.39% Upside)
Insider Transactions
Bought Shares
Worth $108.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.00%
12-Months-Change
Fundamentals
Return on Equity
-50.81%
Trailing 12-Months
Asset Growth
382.12%
Trailing 12-Months
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use, specifically for canine and equine osteoarthritis. Eupraxia's broader development portfolio includes EP-201, an antibiotic aimed at preventing post-surgical site infections, and EP-105, an extended-release anesthetic designed for extended post-operative pain relief. Furthermore, the company is actively developing product candidates for oncology applications. Established in 2011 and headquartered in Victoria, Canada, Eupraxia Pharmaceuticals Inc. was formerly known as Plaza Capital Partners Inc. until its renaming in May 2012.
EPRX Stock 12 Month Forecast
Average Price Target
$16.50
▲(132.39% Upside)
Technical Analysis
Ownership Overview
10.65% Insiders
0.03% Mutual Funds
25.37% Other Institutional Investors
63.80% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---